Precision Medicine Group acquired Project Farma, a patient-focused bioengineering services firm that supports life science innovators in the manufacturing and scale-up of advanced therapies.
Backed by Leaps by Bayer, Bay Area-based Senti Biosciences secured $105 million in a Series B financing round that will help the company advance its therapeutic pipeline of allogeneic chimeric antigen receptor natural killer (CAR-NK) cell therapies.
Thermo Fisher Scientific is significantly expanding the company’s footprint with new facilities in the United States and in Europe.
Immunai, a company comprehensively mapping the immune system, announced a collaboration with leading life science technology company 10x Genomics.
Days after Bayer announced a new cell and gene therapy strategy to maximize the capabilities of some recent acquisitions, the Germany-based life sciences giant is jumping into the CAR-T space and expanding the company’s oncology focus through a collaboration with Bay Area-based Atara Biotherapeutics.
Less than two months after life sciences giant Bayer acquired N.C.-based gene therapy company AskBio, the healthcare company launched a cell and gene therapy platform within its pharmaceutical division.
Bayer is making a big bet on gene therapy with the acquisition of North Carolina-based Asklepios BioPharmaceutical (AskBio).
Takeda Pharmaceutical opened a new 24,000-square-foot R&D cell therapy manufacturing facility in Boston at the site of the company’s R&D headquarters.
Celyad Oncology is at the forefront of cutting-edge immunotherapy and is hopeful of providing a new way forward for patients with relapsed/refractory multiple myeloma.
With a $30 million investment, Versant Ventures launched Matterhorn Biosciences AG, a company developing T cell receptor therapies based on the recent discovery of MR1-restricted T (MRIT) cells that recognize and kill a wide range of tumors of various tissue origins.